UroGen Historical Balance Sheet

URGN Stock

USD 12.70 0.04 0.32%

Trend analysis of UroGen Pharma balance sheet accounts such as Total Assets of 98.8 M, Other Current Liab of 25.9 M, Total Current Liabilities of 32.8 M or Property Plant And Equipment Net of 2.1 M provides information on UroGen Pharma's total assets, liabilities, and equity, which is the actual value of UroGen Pharma to its prevalent stockholders. By breaking down trends over time using UroGen Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining UroGen Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether UroGen Pharma is a good buy for the upcoming year.

UroGen Pharma Inventory

3.16 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

About UroGen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of UroGen Pharma at a specified time, usually calculated after every quarter, six months, or one year. UroGen Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of UroGen Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which UroGen currently owns. An asset can also be divided into two categories, current and non-current.

UroGen Pharma Balance Sheet Chart

At this time, UroGen Pharma's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 1st of December 2024, Common Stock is likely to grow to about 93.5 K, while Total Assets are likely to drop about 98.8 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net Long Term Debt Total Inventory

Add Fundamental

Total Assets

Total assets refers to the total amount of UroGen Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in UroGen Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on UroGen Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of UroGen Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from UroGen Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 1st of December 2024, Common Stock is likely to grow to about 93.5 K, while Total Assets are likely to drop about 98.8 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	16.6M	17.4M	24.7M	25.9M
Total Assets	119.7M	136.2M	178.3M	98.8M

Other Current Liab Total Assets

UroGen Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Common Stock Total Equity	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Property Plant And Equipment Gross
Total Assets		0.83	0.87	0.22	0.13	0.89	-0.26	-0.76	0.82	0.79	0.69	0.99	0.91	0.62	0.87	0.58	0.99	0.88	0.8	0.91	0.95	0.85	0.83	0.53	0.92	0.76
Other Current Liab	0.83		0.99	-0.2	-0.3	0.8	-0.01	-0.97	0.64	0.71	0.41	0.8	0.86	0.89	0.99	0.86	0.85	0.96	0.65	0.71	0.88	0.57	0.64	0.82	0.91	0.91
Total Current Liabilities	0.87	0.99		-0.17	-0.26	0.79	-0.07	-0.96	0.76	0.77	0.41	0.86	0.9	0.89	1.0	0.85	0.9	0.99	0.64	0.79	0.92	0.66	0.72	0.81	0.92	0.88
Total Stockholder Equity	0.22	-0.2	-0.17		0.99	0.24	-0.78	0.4	0.11	0.18	0.55	0.26	0.0	-0.57	-0.16	-0.63	0.13	-0.11	0.55	0.24	0.05	0.49	0.2	-0.68	-0.05	-0.02
Net Tangible Assets	0.13	-0.3	-0.26	0.99		0.19	-0.75	0.48	0.04	0.1	0.48	0.17	-0.08	-0.63	-0.26	-0.71	0.04	-0.21	0.48	0.18	-0.02	0.42	0.14	-0.75	-0.12	-0.15
Property Plant And Equipment Net	0.89	0.8	0.79	0.24	0.19		-0.25	-0.71	0.59	0.66	0.68	0.86	0.84	0.59	0.82	0.49	0.86	0.77	0.91	0.79	0.87	0.71	0.72	0.43	0.9	0.67
Net Debt	-0.26	-0.01	-0.07	-0.78	-0.75	-0.25		-0.14	-0.37	-0.54	-0.15	-0.35	-0.22	0.29	-0.06	0.41	-0.26	-0.12	-0.5	-0.41	-0.25	-0.55	-0.38	0.47	-0.14	-0.1
Retained Earnings	-0.76	-0.97	-0.96	0.4	0.48	-0.71	-0.14		-0.65	-0.66	-0.26	-0.73	-0.84	-0.97	-0.97	-0.94	-0.81	-0.93	-0.48	-0.67	-0.85	-0.47	-0.61	-0.91	-0.9	-0.8
Accounts Payable	0.82	0.64	0.76	0.11	0.04	0.59	-0.37	-0.65		0.84	0.3	0.87	0.82	0.56	0.72	0.54	0.87	0.79	0.46	0.89	0.85	0.86	0.84	0.49	0.74	0.5
Cash	0.79	0.71	0.77	0.18	0.1	0.66	-0.54	-0.66	0.84		0.25	0.86	0.83	0.52	0.75	0.46	0.85	0.79	0.63	0.84	0.84	0.78	0.8	0.41	0.78	0.65
Non Current Assets Total	0.69	0.41	0.41	0.55	0.48	0.68	-0.15	-0.26	0.3	0.25		0.63	0.43	0.09	0.43	0.12	0.56	0.41	0.77	0.43	0.46	0.64	0.38	0.07	0.47	0.53
Cash And Short Term Investments	0.99	0.8	0.86	0.26	0.17	0.86	-0.35	-0.73	0.87	0.86	0.63		0.91	0.59	0.85	0.55	0.99	0.88	0.79	0.94	0.96	0.89	0.86	0.49	0.9	0.75
Common Stock Shares Outstanding	0.91	0.86	0.9	0.0	-0.08	0.84	-0.22	-0.84	0.82	0.83	0.43	0.91		0.75	0.89	0.68	0.94	0.88	0.69	0.84	0.93	0.69	0.85	0.63	0.93	0.73
Other Current Assets	0.62	0.89	0.89	-0.57	-0.63	0.59	0.29	-0.97	0.56	0.52	0.09	0.59	0.75		0.89	0.97	0.69	0.85	0.3	0.57	0.75	0.31	0.51	0.96	0.8	0.67
Other Stockholder Equity	0.87	0.99	1.0	-0.16	-0.26	0.82	-0.06	-0.97	0.72	0.75	0.43	0.85	0.89	0.89		0.85	0.89	0.98	0.66	0.78	0.92	0.64	0.7	0.8	0.93	0.88
Total Liab	0.58	0.86	0.85	-0.63	-0.71	0.49	0.41	-0.94	0.54	0.46	0.12	0.55	0.68	0.97	0.85		0.64	0.82	0.2	0.48	0.68	0.29	0.45	1.0	0.72	0.7
Total Current Assets	0.99	0.85	0.9	0.13	0.04	0.86	-0.26	-0.81	0.87	0.85	0.56	0.99	0.94	0.69	0.89	0.64		0.91	0.74	0.94	0.98	0.83	0.86	0.59	0.94	0.75
Common Stock	0.88	0.96	0.99	-0.11	-0.21	0.77	-0.12	-0.93	0.79	0.79	0.41	0.88	0.88	0.85	0.98	0.82	0.91		0.64	0.83	0.93	0.7	0.75	0.78	0.9	0.87
Property Plant Equipment	0.8	0.65	0.64	0.55	0.48	0.91	-0.5	-0.48	0.46	0.63	0.77	0.79	0.69	0.3	0.66	0.2	0.74	0.64		0.69	0.72	0.72	0.64	0.14	0.72	0.68
Long Term Debt	0.91	0.71	0.79	0.24	0.18	0.79	-0.41	-0.67	0.89	0.84	0.43	0.94	0.84	0.57	0.78	0.48	0.94	0.83	0.69		0.95	0.86	0.88	0.43	0.85	0.57
Common Stock Total Equity	0.95	0.88	0.92	0.05	-0.02	0.87	-0.25	-0.85	0.85	0.84	0.46	0.96	0.93	0.75	0.92	0.68	0.98	0.93	0.72	0.95		0.79	0.84	0.62	0.97	0.73
Short Term Investments	0.85	0.57	0.66	0.49	0.42	0.71	-0.55	-0.47	0.86	0.78	0.64	0.89	0.69	0.31	0.64	0.29	0.83	0.7	0.72	0.86	0.79		0.73	0.23	0.68	0.54
Long Term Debt Total	0.83	0.64	0.72	0.2	0.14	0.72	-0.38	-0.61	0.84	0.8	0.38	0.86	0.85	0.51	0.7	0.45	0.86	0.75	0.64	0.88	0.84	0.73		0.4	0.76	0.55
Non Current Liabilities Total	0.53	0.82	0.81	-0.68	-0.75	0.43	0.47	-0.91	0.49	0.41	0.07	0.49	0.63	0.96	0.8	1.0	0.59	0.78	0.14	0.43	0.62	0.23	0.4		0.67	0.65
Capital Surpluse	0.92	0.91	0.92	-0.05	-0.12	0.9	-0.14	-0.9	0.74	0.78	0.47	0.9	0.93	0.8	0.93	0.72	0.94	0.9	0.72	0.85	0.97	0.68	0.76	0.67		0.74
Property Plant And Equipment Gross	0.76	0.91	0.88	-0.02	-0.15	0.67	-0.1	-0.8	0.5	0.65	0.53	0.75	0.73	0.67	0.88	0.7	0.75	0.87	0.68	0.57	0.73	0.54	0.55	0.65	0.74

Click cells to compare fundamentals

UroGen Pharma Account Relationship Matchups

UroGen Pharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	202.4M	122.0M	119.7M	136.2M	178.3M	98.8M
Other Current Liab	14.8M	18.2M	16.6M	17.4M	24.7M	25.9M
Total Current Liabilities	19.5M	21.4M	22.4M	23.9M	31.2M	32.8M
Total Stockholder Equity	180.3M	96.4M	8.4M	(88.7M)	(65.2M)	(62.0M)
Net Tangible Assets	180.3M	96.4M	8.4M	(89.4M)	(102.8M)	(97.6M)
Property Plant And Equipment Net	4.7M	4.2M	3.1M	3.7M	2.4M	2.1M
Net Debt	(47.1M)	(102.4M)	(44.0M)	43.7M	4.4M	4.6M
Retained Earnings	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(679.3M)	(645.4M)
Accounts Payable	4.7M	3.3M	5.8M	5.5M	6.5M	4.3M
Cash	49.7M	103.9M	44.4M	55.4M	95.0M	53.3M
Non Current Assets Total	53.8M	6.4M	5.4M	6.7M	9.1M	8.5M
Cash And Short Term Investments	147.1M	103.9M	89.8M	100.0M	137.0M	79.8M
Common Stock Shares Outstanding	20.5M	21.8M	22.3M	22.8M	28.8M	17.0M
Liabilities And Stockholders Equity	202.4M	122.0M	119.7M	136.2M	178.3M	98.8M
Other Current Assets	1.0M	4.6M	8.7M	11.9M	11.1M	11.7M
Other Stockholder Equity	408.0M	452.5M	475.7M	487.8M	614.0M	644.7M
Total Liab	22.1M	25.7M	111.3M	225.0M	243.5M	255.7M
Total Current Assets	148.6M	115.6M	114.4M	128.9M	169.2M	90.2M
Accumulated Other Comprehensive Income	276K	271K	(25K)	(107K)	12K	12.6K
Common Stock	57K	60K	61K	63K	89K	93.5K
Property Plant Equipment	4.7M	4.2M	2.0M	1.3M	1.5M	1.7M
Common Stock Total Equity	57K	60K	61K	63K	72.5K	45.9K
Non Current Liabilities Total	2.6M	4.2M	89.0M	201.1M	212.3M	222.9M
Capital Surpluse	408.0M	452.5M	475.7M	487.8M	561.0M	307.7M
Property Plant And Equipment Gross	4.7M	4.2M	2.0M	1.3M	6.3M	6.6M
Non Currrent Assets Other	487K	289K	1.5M	2.7M	2.3M	2.4M
Other Assets	487K	289K	29.9K	620K	713K	367.9K
Net Invested Capital	180.3M	96.4M	8.4M	8.2M	33.3M	55.5M
Net Working Capital	129.2M	94.2M	92.0M	105.0M	138.0M	112.3M
Retained Earnings Total Equity	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(519.4M)	(545.4M)
Capital Stock	57K	60K	61K	63K	89K	68.6K

Pair Trading with UroGen Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against UroGen Stock

0.71	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.7	EWTX	Edgewise Therapeutics	Pair Corr
0.68	BHC	Bausch Health Companies	Pair Corr
0.67	GILD	Gilead Sciences	Pair Corr
0.56	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.

The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Historical Balance Sheet

UroGen Pharma Inventory

3.16 Million

About UroGen Balance Sheet Analysis

UroGen Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

UroGen Pharma balance sheet Correlations

UroGen Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

UroGen Pharma balance sheet Accounts

Pair Trading with UroGen Pharma

Moving against UroGen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Current Liabilities
Non Current Liabilities Total	+ 1.0	Total Liab
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Other Current Liab

Other Stockholder Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.96	Total Current Liabilities
Total Liab	- 0.94	Retained Earnings
Common Stock	- 0.93	Retained Earnings